

**Q1–FY2017
Conference Call
Presentation**

July 12th, 2016

CAUTION REGARDING NON-IFRS FINANCIAL MEASURES

The Company uses adjusted financial measures, including Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) and non-IFRS operating loss (Operating loss before interest, taxes, depreciation and amortization), to assess its operating performance. These non-IFRS financial measures are directly derived from the Company's financial statements and are presented in a consistent manner. The Company uses these measures for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to IFRS measures, allows them to see the Company's results through the eyes of management, and to better understand its historical and future financial performance.

Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Adjusted EBITDA and non-IFRS operating loss to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our operating performance, and because the Corporation believes it provides meaningful information on the Corporation financial condition and operating results. Neptune's method for calculating Adjusted EBITDA or non-IFRS operating loss may differ from that used by other corporations.

Neptune obtains its Consolidated Adjusted EBITDA and non-IFRS operating loss measurement by adding to net income (loss), finance costs, depreciation and amortization and income taxes and by subtracting finance income. Other items such as insurance recoveries from plant explosion and acquisition costs that do not impact core operating performance of the Corporation are excluded from the calculation as they may vary significantly from one period to another. Finance income/costs include foreign exchange gain (loss) and change in fair value of derivatives. Neptune also excludes the effects of certain non-monetary transactions recorded, such as stock-based compensation, acquisition costs and insurance recoveries, from its Adjusted EBITDA and non-IFRS operating loss calculation. The Company believes it is useful to exclude this item as it is a non-cash expense. Excluding this item does not imply it is necessarily non-recurring.

CAUTIONARY NOTE AND FORWARD-LOOKING STATEMENT

This presentation contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks, may involve, but are not limited to, comments with respect to the Company's business or financial objectives, its strategies or future actions, its targets, expectations for financial condition or outlook for operations and future contingent payments. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management's perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. The Company considers these assumptions to be reasonable based on information currently available to it, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business.

For additional information with respect to these and other factors and assumptions underlying the forward-looking statements made in this presentation, see the Company's quarterly and annual Management Discussion and Analysis filed with the Canadian securities commissions. The forward-looking information set forth herein reflects the Company's expectations as at the date of this presentation and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.



HIGHLIGHTS NUTRACEUTICAL

- Achieved record quarterly revenues of \$11.3 million, a 270% growth over last year - solid contribution of **Solutions** (Biodroga) and **Ingredients** (Krill oil) including first sales in China
- Second sequentially positive quarterly Adjusted EBITDA, which totaled \$1.1 million compared to a loss of \$3.2 million a year ago
- Positive variance reflects continued improvement from operating efficiencies, contribution of **Solutions** and higher sales volume of **Ingredients**
- Completed first sales of MaxSimil® in July
- New corporate branding to reflect our new Vision, Mission and diversified strategy

A **Nutrition Products** company focused on **Wellness Solutions**

- Good performance of krill business in the first quarter and good momentum in the current quarter
- Continued improved operations and manufacturing cost base in the past 12 months
- Growing opportunities via value-added unique product forms
- Canada now one of only two countries that can export krill oil to China
 - Completed first sales in current quarter



OUR VISION, MISSION AND BRAND

- Vision:

Provide great nutrition solutions that deliver optimal health and wellness


- Mission:

Leverage our scientific and innovative expertise to create and provide our customers globally with the best nutritional products and wellness solutions






NEPTUNE TODAY ... A NUTRITION PRODUCTS COMPANY



- MaxSimil[®] is a novel, patented delivery platform that enhances the absorption of lipid-based and lipid-soluble nutraceuticals
- It mimics the human digestive process to deliver absorption-ready, pre-digested lipid-based products such as Omega-3 fish oils
- Statistically significant results indicated that the EPA+DHA from MaxSimil[®] fish oils were absorbed 3 times faster than the regular fish oils in a Phase I clinical study
- Neptune has the exclusive rights to North America and first sales completed in July 2016



SOLUTIONS – THE PATH TO CREATING VALUE ...



2



3



5





NUTRACEUTICAL – Q1-2017 RESULTS

(In thousands of CAD \$, except for loss per share)	Q1-2017		Q1-2016		Q1-2017 VS Q1-2016	Q4-2016		Q1-2017 VS Q4-2016
	CAD \$	% of Sales	CAD \$	% of Sales	% of variation	CAD \$	% of Sales	% of variation
Revenues from sales	11,127		2,655		319%	9,415		18%
Gross margin on sales	3,390	31%	(1,146)	(43%)		2,502	27%	35%
Royalties revenues	127		386			617		
Total gross margin as per FS	3,517		(759)			3,119		
R&D	395	4%	406	15%	(3%)	108	1%	266%
SG&A	3,191	29%	2,991	113%	7%	3,460	37%	(8%)
Adjusted EBITDA (Non-IFRS operating loss)	1,138	10%	(3,223)	(121%)	135%	658	7%	73%
Net income (loss)	(1,250)		(4,526)			963*		
Net loss – CONSO	(3,824)		(4,966)			(379)		
Basic and diluted loss per share - CONSO	(0.03)		(0.06)			0.01		

*Includes \$2 million of deferred tax recovery




PRODUCTIVITY INITIATIVES – TURBO PROJECT

- Company-wide initiative to drive efficiencies and operating performance
- Started in the second quarter of Fiscal 2016
- As of May 31st, 2016, approximately 70% of total expected cost savings, of approximately \$5.0 million, were realized
- Full impact expected at the end of Fiscal 2017
- Productivity initiatives driving margin improvements



OUR RESULTS LAST 6 QUARTERS


QUARTERLY NUTRACEUTICAL REVENUES





OUR RESULTS LAST 6 QUARTERS

QUARTERLY NUTRACEUTICAL ADJUSTED EBITDA



* \$4M of Inventory write-off



LOOKING AHEAD

- Continue to drive our growth by providing great nutrition solutions that deliver optimal health and well-being

- Growth path:

Solutions	Scale-up / Invest in capabilities
Speciality ingredients	In-house innovation leveraging Site capabilities/ Licensing agreements
Consumer brands	Acquire and expand distribution

- NKO[®]: Continue growth via new product form, markets such as China, and great customer focus
- Continue to lever benefits of operating effectiveness and cost-saving initiatives on margins
- For Fiscal 2017 in the Nutraceutical segment, we expect revenues to be greater than \$43 million with a double-digit Adjusted EBITDA margin

THANK YOU

Q1-2017 Conference
Call Presentation